Nucana Plc ADR (NCNA)

$1.86 -0.04 (-2.11%)
Market Cap 58,000.00
Revenue (ttm) 0.00
Net Income (ttm) -24.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 54,600
Avg Vol 62,484
Day's Range N/A - N/A
Shares Out 30,000.00
Stochastic %K 3%
Beta 1.69
Analysts Strong Buy
Price Target $25.00

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 13 1357 1111
Address:
3 Lochside Way, Edinburgh, United Kingdom
ChickenClaw
ChickenClaw Mar. 17 at 3:26 PM
$NCNA
0 · Reply
ChickenClaw
ChickenClaw Mar. 17 at 3:24 PM
$NCNA
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 17 at 2:57 PM
$NCNA
0 · Reply
TheStonkMan2000
TheStonkMan2000 Mar. 17 at 2:45 PM
$NCNA Bahahahaha, this chart........these baggies. Bahahahaha
0 · Reply
ChickenClaw
ChickenClaw Mar. 17 at 2:11 PM
$NCNA
0 · Reply
Xmarketsthestock
Xmarketsthestock Mar. 17 at 1:14 PM
$NCNA stop listening to the bulls... they were adament that after RS it would rally. It rallied the wrong way. Company has been silent. Even the last few press releases were pointless... not even a pump n dump. More like just dump.
0 · Reply
TVanda00
TVanda00 Mar. 16 at 9:29 PM
$NCNA Finding lots of biotech charts that have taken a path similar to this.
1 · Reply
FickleFin
FickleFin Mar. 16 at 6:51 PM
$NCNA at this point pure embarassment...
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 16 at 5:50 PM
$NCNA And Yes wins it on the first day of the week…
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 16 at 12:35 PM
$NCNA Another 52 week low this week? yes or no…
0 · Reply
Latest News on NCNA
NuCana Appoints Theresa Bruce as Chief Operating Officer

Jan 6, 2026, 8:00 AM EST - 2 months ago

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Dec 10, 2025, 8:00 AM EST - 3 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 4 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Nov 5, 2025, 8:00 AM EST - 4 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 5, 2025, 8:00 AM EDT - 6 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Sep 3, 2025, 8:00 AM EDT - 6 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 20, 2025, 4:05 PM EDT - 7 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

NuCana Announces ADS Ratio Change

Aug 1, 2025, 4:05 PM EDT - 8 months ago

NuCana Announces ADS Ratio Change

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 21, 2025, 8:05 AM EDT - 8 months ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

NuCana Announces Plan to Implement ADS Ratio Change

Jul 11, 2025, 10:30 AM EDT - 8 months ago

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Jun 2, 2025, 4:01 PM EDT - 10 months ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 8:36 AM EDT - 1 year ago

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 1 year ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 1, 2024, 4:01 PM EDT - 2 years ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

NuCana: Potential Turnaround In 2024 But Risky

Jan 3, 2024, 2:39 AM EST - 2 years ago

NuCana: Potential Turnaround In 2024 But Risky

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

NuCana to Present at the Jefferies London Healthcare Conference

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

NuCana to Present at the Jefferies Healthcare Conference

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Receipt of Nasdaq Notice

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

NuCana to Participate in Two Upcoming Investor Conferences

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

Jan 8, 2023, 4:30 AM EST - 3 years ago

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

NuCana Announces Receipt of NASDAQ Notice

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22, 2022, 3:40 PM EDT - 3 years ago

NuCana: An Intriguing 'Sum Of The Parts' Story

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 6, 2022, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

ChickenClaw
ChickenClaw Mar. 17 at 3:26 PM
$NCNA
0 · Reply
ChickenClaw
ChickenClaw Mar. 17 at 3:24 PM
$NCNA
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 17 at 2:57 PM
$NCNA
0 · Reply
TheStonkMan2000
TheStonkMan2000 Mar. 17 at 2:45 PM
$NCNA Bahahahaha, this chart........these baggies. Bahahahaha
0 · Reply
ChickenClaw
ChickenClaw Mar. 17 at 2:11 PM
$NCNA
0 · Reply
Xmarketsthestock
Xmarketsthestock Mar. 17 at 1:14 PM
$NCNA stop listening to the bulls... they were adament that after RS it would rally. It rallied the wrong way. Company has been silent. Even the last few press releases were pointless... not even a pump n dump. More like just dump.
0 · Reply
TVanda00
TVanda00 Mar. 16 at 9:29 PM
$NCNA Finding lots of biotech charts that have taken a path similar to this.
1 · Reply
FickleFin
FickleFin Mar. 16 at 6:51 PM
$NCNA at this point pure embarassment...
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 16 at 5:50 PM
$NCNA And Yes wins it on the first day of the week…
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 16 at 12:35 PM
$NCNA Another 52 week low this week? yes or no…
0 · Reply
Wohlstandsradler
Wohlstandsradler Mar. 16 at 9:45 AM
$NCNA March presentation is online.
1 · Reply
GI812
GI812 Mar. 13 at 8:14 PM
$NCNA Any idea when the next update on NUC-3373 in Combination with Anti-PD-1 Therapy will be posted? Somebody - Anybody. 🤮
1 · Reply
GreenEnergy1
GreenEnergy1 Mar. 13 at 2:27 PM
$NCNA
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 13 at 2:25 PM
$NCNA Another 52 week low was touched today!
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 12 at 2:43 PM
$NCNA Nucana is putting on a clinic called ”how to drain every penny from every possible investor”. Is a Master Class actually!
0 · Reply
Baseball89
Baseball89 Mar. 12 at 2:29 PM
$NCNA we need news soon. This is ridiculous.
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 12 at 11:26 AM
$NCNA Earnings for 2025 = -$24 million. That’s a lot of negative!
0 · Reply
GreenEnergy1
GreenEnergy1 Mar. 11 at 8:48 PM
$NCNA Another 52 wee low hit today! Trading below $.01 pre reverse split!
0 · Reply
stwix
stwix Mar. 11 at 8:28 PM
$NCNA the moment of truth is getting close - next week we should learn how insider ownership evolved. I am not saying it is a make or break for me but would be reassuring to see some engagement.
1 · Reply
GreenEnergy1
GreenEnergy1 Mar. 11 at 3:42 PM
$NCNA Another big day with updates, volume and excitement. I can’t understand why Nucana isn’t on Jim Cramer’s mind all the time.
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 11 at 1:49 AM
New Video out on the Bullish Analysis on $RR $NCNA $ATOM.X $ICU $XWEL and more! https://www.youtube.com/watch?v=Pu9GaPofm5A
3 · Reply
TVanda00
TVanda00 Mar. 10 at 10:34 PM
$NCNA 🤷🏻‍♂️🤷
0 · Reply